Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Summary

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Previously Treated Non-Small Cell Lung Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2/3

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

SWOG Cancer Research Network

Last updated on ClinicalTrials.gov

May 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

+796 more sites listed on ClinicalTrials.gov